Health Care [ 4/12 ] | Pharmaceuticals [ 15/75 ]
NASDAQ | Common Stock
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States.
The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions.
Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 3, 26 | -0.16 Increased by +84.16% | -0.15 Decreased by -6.67% |
| Nov 6, 25 | -0.12 Decreased by -9.09% | -0.13 Increased by +7.69% |
| Aug 7, 25 | -0.13 Increased by +13.33% | -0.14 Increased by +7.14% |
| Jun 6, 25 | -0.12 Increased by +50.00% | -0.29 Increased by +58.62% |
| Feb 25, 25 | -1.01 Decreased by -4.95 K% | -0.38 Decreased by -169.33% |
| Nov 4, 24 | -0.11 Increased by +73.17% | -0.01 Decreased by -1.00 K% |
| Aug 7, 24 | -0.15 Increased by +64.29% | -0.20 Increased by +25.00% |
| May 7, 24 | -0.24 Increased by +40.00% | -0.29 Increased by +17.24% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 1.29 M Decreased by -85.94% | -19.80 M Increased by +79.50% | Decreased by -1.53 K% Decreased by -45.82% |
| Sep 30, 25 | 3.30 M Decreased by -24.09% | -14.61 M Decreased by -92.64% | Decreased by -442.98% Decreased by -153.78% |
| Jun 30, 25 | 1.78 M Decreased by -35.76% | -15.43 M Decreased by -40.44% | Decreased by -868.26% Decreased by -118.61% |
| Mar 31, 25 | 1.46 M Decreased by -39.32% | -15.09 M Increased by +10.96% | Decreased by -1.04 K% Decreased by -46.75% |
| Dec 31, 24 | 9.21 M Decreased by -47.58% | -96.55 M Decreased by -6.38 K% | Decreased by -1.05 K% Decreased by -12.25 K% |
| Sep 30, 24 | 4.35 M Decreased by -53.18% | -7.59 M Increased by +74.07% | Decreased by -174.55% Increased by +44.63% |
| Jun 30, 24 | 2.77 M Increased by +47.99% | -10.99 M Increased by +62.85% | Decreased by -397.18% Increased by +74.90% |
| Mar 31, 24 | 2.40 M Decreased by -5.14% | -16.94 M Increased by +39.84% | Decreased by -706.46% Increased by +36.58% |